GT Biopharma (GTBP) Competitors $2.15 +0.02 (+1.17%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GTBP vs. COCP, NNVC, GLYC, MRKR, ATHA, MEIP, QNTM, AFMD, SLGL, and SPRBShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Cocrystal Pharma (COCP), NanoViricides (NNVC), GlycoMimetics (GLYC), Marker Therapeutics (MRKR), Athira Pharma (ATHA), MEI Pharma (MEIP), Quantum Biopharma (QNTM), Affimed (AFMD), Sol-Gel Technologies (SLGL), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Cocrystal Pharma NanoViricides GlycoMimetics Marker Therapeutics Athira Pharma MEI Pharma Quantum Biopharma Affimed Sol-Gel Technologies Spruce Biosciences Cocrystal Pharma (NASDAQ:COCP) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings. Do analysts prefer COCP or GTBP? Cocrystal Pharma currently has a consensus price target of $7.00, suggesting a potential upside of 258.97%. GT Biopharma has a consensus price target of $11.00, suggesting a potential upside of 411.63%. Given GT Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe GT Biopharma is more favorable than Cocrystal Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is COCP or GTBP more profitable? Cocrystal Pharma's return on equity of -94.62% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% GT Biopharma N/A -257.47%-131.09% Which has higher earnings & valuation, COCP or GTBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.85-1.05GT BiopharmaN/AN/A-$7.60MN/AN/A Which has more risk and volatility, COCP or GTBP? Cocrystal Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Does the media prefer COCP or GTBP? In the previous week, GT Biopharma had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for Cocrystal Pharma. GT Biopharma's average media sentiment score of 1.50 beat Cocrystal Pharma's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Cocrystal Pharma Neutral GT Biopharma Very Positive Do insiders and institutionals believe in COCP or GTBP? 6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by insiders. Comparatively, 10.9% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor COCP or GTBP? GT Biopharma received 93 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2477.42% Underperform Votes722.58% GT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% SummaryGT Biopharma beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.76M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.406.717.644.62Net Income-$7.60M$138.33M$3.18B$245.85M7 Day Performance0.47%-2.61%-1.99%-2.68%1 Month Performance-9.28%-2.32%-0.42%-2.19%1 Year Performance-48.77%-5.31%16.51%12.84% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.9337 of 5 stars$2.15+0.9%$11.00+411.6%-47.6%$4.76MN/A0.008Positive NewsCOCPCocrystal Pharma2.6083 of 5 stars$1.87+0.5%$7.00+274.3%+32.7%$19.02MN/A-1.0110NNVCNanoViricidesN/A$1.35+4.7%N/A+21.0%$18.83MN/A-1.7820Gap UpGLYCGlycoMimetics4.1636 of 5 stars$0.29+2.2%$8.00+2,658.6%-90.1%$18.70M$10,000.000.0050Analyst ForecastNews CoverageGap DownHigh Trading VolumeMRKRMarker Therapeutics4.3474 of 5 stars$1.72+1.2%$19.00+1,004.7%-59.9%$18.42M$3.31M0.0060ATHAAthira Pharma2.9125 of 5 stars$0.47+6.4%$13.83+2,855.8%-88.3%$18.10MN/A-0.1640MEIPMEI Pharma4.1543 of 5 stars$2.69-1.1%$7.00+160.2%-41.1%$17.92M$65.30M-0.38100Analyst ForecastGap DownQNTMQuantum BiopharmaN/A$9.02-15.3%N/AN/A$17.32MN/A-0.59N/AAFMDAffimed4.0731 of 5 stars$1.06flat$13.50+1,173.6%-80.2%$17.07M$8.95M0.00200SLGLSol-Gel Technologies2.6005 of 5 stars$0.61-1.0%$5.00+719.7%-47.7%$17.00M$1.55M-1.7950Gap DownSPRBSpruce Biosciences3.5026 of 5 stars$0.41-1.1%$3.90+861.8%-91.9%$16.75M$10.09M-0.4320Gap Up Related Companies and Tools Related Companies Cocrystal Pharma Alternatives NanoViricides Alternatives GlycoMimetics Alternatives Marker Therapeutics Alternatives Athira Pharma Alternatives MEI Pharma Alternatives Quantum Biopharma Alternatives Affimed Alternatives Sol-Gel Technologies Alternatives Spruce Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTBP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts